药理学稳定TYK2假激酶结构域可阻断小鼠和人类自身免疫通路
TYK2失活编码变异可高保护常见自身免疫病而无免疫缺陷。BMS-986165通过优化结合TYK2调控域,变构高选择性阻断受体刺激的TYK2激活;在1期临床试验中体外和体内均阻断人TH17、TH1、B细胞和髓系细胞的信号与功能反应;在狼疮肾炎和炎症性肠病小鼠模型中展现稳健疗效。
要点
- BMS-986165通过优化结合TYK2调控域,变构高选择性阻断受体刺激的TYK2激活。
- 1期临床试验中,BMS-986165在体外和体内阻断人TH17、TH1、B细胞和髓系细胞的信号与功能反应。
- BMS-986165在狼疮肾炎和炎症性肠病小鼠模型中展现稳健疗效,支持其治疗多种免疫介导疾病的潜力。
核心结论
- BMS-986165通过药理学稳定TYK2假激酶结构域,阻断小鼠和人类的自身免疫通路,支持其治疗多种免疫介导疾病的潜力。
研究设计与样本
- 包含1期临床试验以及狼疮肾炎和炎症性肠病小鼠模型的研究,评估BMS-986165对TYK2激活及自身免疫相关细胞反应的作用。
主要发现
- BMS-986165在体外和1期临床试验体内均阻断人TH17、TH1、B细胞和髓系细胞的信号与功能反应。
- BMS-986165在狼疮肾炎和炎症性肠病小鼠模型中展现稳健疗效,与阻断多条自身免疫通路一致。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TYK2 is a nonreceptor tyrosine kinase involved in adaptive and innate immune responses. A deactivating coding variant has previously been shown to prevent receptor-stimulated activation of this kinase and provides high protection from several common autoimmune diseases but without immunodeficiency. An agent that recapitulates the phenotype of this deactivating coding variant may therefore represent an important advancement in the treatment of autoimmunity. BMS-986165 is a potent oral agent that similarly blocks receptor-stimulated activation of TYK2 allosterically and with high selectivity and potency afforded through optimized binding to a regulatory domain of the protein. Signaling and functional responses in human TH17, TH1, B cells, and myeloid cells integral to autoimmunity were blocked by BMS-986165, both in vitro and in vivo in a phase 1 clinical trial. BMS-986165 demonstrated robust efficacy, consistent with blockade of multiple autoimmune pathways, in murine models of lupus nephritis and inflammatory bowel disease, supporting its therapeutic potential for multiple immune-mediated diseases.
引用
- Burke JR, Cheng L, Gillooly KM, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med. 2019. PMID: 31341059. doi:10.1126/scitranslmed.aaw1736
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。